User login
Myelodysplastic syndromes: etiologies, evaluation, and therapy
In this interview, Dr David Henry, MD, the Editor-in-Chief of JCSO, and David Steensma, MD, of the Dana-Farber Cancer Institute in Boston, talk about myelodysplasic syndromes, from diagnosis, evaluation, and etiologies, to therapy options and molecular sequencing.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
In this interview, Dr David Henry, MD, the Editor-in-Chief of JCSO, and David Steensma, MD, of the Dana-Farber Cancer Institute in Boston, talk about myelodysplasic syndromes, from diagnosis, evaluation, and etiologies, to therapy options and molecular sequencing.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
In this interview, Dr David Henry, MD, the Editor-in-Chief of JCSO, and David Steensma, MD, of the Dana-Farber Cancer Institute in Boston, talk about myelodysplasic syndromes, from diagnosis, evaluation, and etiologies, to therapy options and molecular sequencing.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
Diabetes management in cancer patients
In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.
Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.
Recognition of latest CLL therapies highlights new options for other cancers
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.